TickerTalks
Browse all tickers →
TickerTalks›$LAB
LALAB

Standard BioTools Inc.

Rising onWhy it's trendingStrong bearish X conversationPrice and volume picking up
$LAB·$360M·Medical - Equipment & Services·Healthcare
$0.84-1.3%YTD-33.2%1Y-32.1%
Mentions · last 7 days
2026-07-04: 2,670 posts2026-07-05: 2,404 posts2026-07-06: 1,144 posts2026-07-07: 1,685 posts2026-07-08: 2,046 posts2026-07-09: 3,225 posts2026-07-10: 1,999 posts15,236
Price updated 3m ago·X counts updated 4d ago
LALAB
$LABStandard BioTools Inc.
$0.84-1.28%15k posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $LAB, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-07-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Two well-known activists now own 37% of Standard BioTools between them — the stock's at the lows, they're at the table.

Standard BioTools makes lab instruments and reagents for cell and protein biology research — a small player in the life-science tools market. The stock trades below $1 and two well-known activist funds have just consolidated more than a third of the shares between them.

  • Casdin Capital (the founding activist) sits at 22.7%, and Viking Global filed a fresh Schedule 13D on June 12 disclosing 15% with explicit engagement intent — 37.7% of shares now sit in actively engaged hands, unusually concentrated and typically the setup that precedes a strategic action rather than a wait-and-see.
  • The financials don't yet back a bull case on their own: Q1 revenue of $21M grew only 4.6% YoY at 53% gross margin and $47M of free cash burn — this is a 'someone forces a sale or a recap' story, not a 'results reaccelerate' story, and the small analyst pool models continued losses through FY28.
  • Shareholder-investigation firms are already circling (Brodsky & Smith notice on June 19 alongside three other names in the release), which historically shows up when a strategic process is either being explored or already leaking — consistent with the Casdin 13D amendment pattern.

The forward path is binary — either the activists successfully drive a sale or merger at a premium to $0.85, or the cash burn forces a dilutive raise that wipes another leg. Watch the next 8-K stack for M&A disclosure and the Aug 10 earnings for cash-runway color.

What to watch: An M&A-related 8-K or a Rule 425 filing would confirm the activist thesis. Aug 10 earnings is the cash-runway checkpoint — anything under ~2 quarters of runway forces a dilutive raise, which is the disconfirming outcome for this coil.

On the calendar: 2026-08-10 — Q2 earnings

float missingsentiment wrong asset

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment143 posts analyzed · as of 2026-07-13

LAB (a crypto token, not an equity) is the week's blowup story: down 66.8% in a single session, market cap collapsing from $4.7B to $1.5B, and down over 90% in a month after coordinated exchange dumping on KuCoin and MEXC. Retail traders are describing wiped-out vesting allocations and 'retirement cancelled' losses, while a handful of scalpers post +$3,000 wins from short trades. Even seemingly bullish takes explicitly warn newcomers to stay away because '99.9% of people lose money' trading it. The only marginally constructive thread notes that the top 10 wallets and some exchanges (Bitget, Gate) still haven't sold, but the dominant tone is that the game is over.

Read the AI verdict + X sentiment for $LAB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Life science tools company offering microfluidics and mass cytometry instruments for drug discovery research.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Equipment & Services sits in its cycle right now — and what that implies for $LAB.

Medical - Equipment & Services · Healthcare

No material change from last week — FDA compounded semaglutide rule clarification and Amazon Pharmacy's GLP-1 entry are resolving in favor of direct-to-patient platforms, lifting the group 3.8% today.

What this means for $LAB

Neutral — Life science tools company offering microfluidics and mass cytometry instruments for drug discovery research; this business's revenue is largely decoupled from the FDA semaglutide clarity and telehealth structural breakout.

Top industry ETF

$IHIiShares U.S. Medical Devices ETF
-17.5%YTD
-16.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-91.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-21.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-20.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
48.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$-0.02$-0.020.0%
Q4 2025Feb 24, 2026$0.06$-0.03+300.0%
Q3 2025Nov 4, 2025$-0.04$-0.03-60.0%
Q2 2025Aug 11, 2025$-0.04$-0.040.0%
Next earningsMon, Aug 10·consensus EPS $-0.01

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$21.1M+4.6%53.5%-44.5%$-0.12$-47.2M
Q4 FY25$23.8M-49.1%43.0%-92.1%$0.05$-1.7M
Q3 FY25$19.6M-56.5%48.5%-120%$-0.09$-23.1M
Q2 FY25$21.8M-3.2%48.8%-109%$-0.09$-22.6M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$82.5M$82.0M – $83.0M-$0.03-$0.03 – -$0.031
FY27$84.1M$83.6M – $84.6M-$0.09-$0.09 – -$0.091
FY28$88.0M$86.9M – $89.2M-$0.08-$0.08 – -$0.081
FY29$89.4M$88.9M – $89.9M-$0.15-$0.15 – -$0.151

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.14%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-26.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.425-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 23 other (13 awards · 8 inkinds · 2 exempts) in window

See when $LAB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Standard BioTools (LAB) held its 2026 Annual Meeting on June 17, 2026 with 390,368,119 shares outstanding. Shareholders approved a new 2026 Equity Incentive Plan and an amendment to the Employee Stock Purchase Plan adding 1,200,000 shares in aggregate. Routine director elections and other governance proposals also passed. No extraordinary compensation or structural changes were disclosed.

SC 13DActivist position (5%+)Jun 12SC 13D
AI summary

Viking Global Investors LP filed an initial Schedule 13D on Standard BioTools Inc. (LAB) as of June 6, 2026, disclosing beneficial ownership of approximately 39,296,310 shares representing 15% of the class (via Viking Global Investors LP) and 10.1% (via the Viking Global Opportunities sub-entities). An initial 13D (rather than passive 13G) from a major hedge fund signals active engagement intent — Viking may seek to influence strategy, governance, or M&A at the life-science tools company.

SC 13D/AActivist amendmentJun 9SC 13D/A
AI summary

Casdin Capital, LLC (investment adviser) filed Amendment No. 8 to Schedule 13D on June 9, 2026, disclosing a 22.7% aggregate beneficial ownership stake (88,783,856 shares) in Standard BioTools Inc. (LAB) as of June 6, 2026. The group includes Casdin Partners Master Fund, Casdin Private Growth Equity Fund II (3.6%), and related entities. The filing is an amendment reflecting updated share counts; at 22.7% with shared voting and dispositive power, Casdin remains the dominant activist/strategic holder and any position changes or engagement disclosures would be highly material to LAB.

8-KMaterial agreementJun 88-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 5.01: Change in control · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

LAB (LAB) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The company announced the appointment of a new officer or director to a senior leadership position. Individuals named in the filing include Standard Bio, Tools Inc. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeJun 38-K — Item 5.02: Officer or director change
AI summary

Standard BioTools Inc. (LAB) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in Chief Financial Officer. Individuals named in the filing include Standard Bio, Tools Inc. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change
AI summary

Standard BioTools Inc. (LAB) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in Chief Executive Officer. Individuals named in the filing include Standard Bio, Tools Inc. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KPress release / Reg FDMay 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Standard BioTools Inc. (LAB) reported financial results for a recent fiscal period in an 8-K filed under Item 2.02. The filing includes key financial metrics including revenue, operating income, and per-share results. Results of operations disclosures under Item 2.02 typically accompany an earnings press release furnished as an exhibit, making them available concurrently with the earnings call. These filings provide the market with transparent, timely financial performance data for investment analysis.

8-KListing / delisting noticeApr 248-K — Item 3.01: Listing / delisting notice
AI summary

Standard BioTools Inc. (LAB) disclosed its addition to Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 under 8-K Item 8.01 (other events). Index inclusions are significant because they trigger automatic buying from passive index funds and ETFs that track the benchmark, often resulting in increased share price and trading volume. Index providers typically announce additions in advance of the effective rebalancing date, giving institutions time to adjust their holdings. The event increases LAB's institutional ownership base and enhances its market visibility and liquidity profile.

+ 13 other (2 13Gs · 2 proxys · 2 8-Ks · 1 425) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)globenewswire.com·25d agoLiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customersbusinesswire.com·28d agoAre ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?prnewswire.com·29d agoLAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholdersgurufocus.com·29d agoLAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com·29d ago

More in Medical - Equipment & Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HIMS$OMCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport